Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $40 from $29 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect the recent positive ABI-5366 data.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating
- Assembly Biosciences Inc. Reports Q3 2025 Earnings
- Assembly Biosciences reports Q3 EPS (72c), consensus (65c)
- Assembly Biosciences announces Phase 1b data for ABI-4334
- ASMB Earnings this Week: How Will it Perform?